Get my own profile
Public access
View all95 articles
4 articles
available
not available
Based on funding mandates
Co-authors
- David ToughGSKVerified email at gsk.com
- emmanuel h demontVP, Head of Medicinal Chemistry and DMPKVerified email at apollotx.com
- Uwe SchaeferSenior Research Associate, The Rockefeller UniversityVerified email at rockefeller.edu
- Robert J WatsonGSKVerified email at gsk.com
- Frank S WalshCEO OssianixVerified email at ossianix.com
- Taylor, SPharmaron UKVerified email at sky.com
- Paul Peter TakCandel Therapeutics, GlaxoSmithKline, Kintai Therapeutics, Academic Medical Center, AmsterdamVerified email at candeltx.com
- Marcus BantscheffCellzome, a GSK companyVerified email at gsk.com
- Gerard DrewesCellzome/GlaxoSmithKline R&DVerified email at gsk.com
- Scott DewellSenior Director, Biodevelopment - CepheidVerified email at cepheid.com
- Wouter de JongeProf of exp Gastroenterology, Amsterdam UMCVerified email at amsterdamumc.nl
- kouzaridesUniversity of CambridgeVerified email at gurdon.cam.ac.uk
- John B DavisUniversity of OxfordVerified email at cmd.ox.ac.uk
- Samuel RobsonProfessor of Genomics and BioinformaticsVerified email at port.ac.uk
- Ben GarciaAssociate Professor, University of Pennsylvania School of MedicineVerified email at mail.med.upenn.edu
- Kate JeffreyVP, Immune Therapeutics Discovery, Moderna. Formerly Harvard Medical School; Massachusetts GeneralVerified email at mgh.harvard.edu
- Ivan MarazziCentre of Epigenetics and MetabolismVerified email at uci.edu
- Brian HuntlyVerified email at cam.ac.uk
- Michael T. McCabeVerified email at gsk.com
- Isabelle BecherEMBL HeidelbergVerified email at embl.de